HA
TEVA icon

Harfst & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Harfst & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$3K – 203
2017
Q2 		$3K Hold
100
– – ﹤0.01% 221
2017
Q1 		$3K Buy
+100
New +$3.41K ﹤0.01% 264
2016
Q1 		– Sell
-100
Closed -$6K – 228
2015
Q4 		$6K Hold
100
– – ﹤0.01% 256
2015
Q3 		$6K Sell
100
-720
-88% -$46.7K ﹤0.01% 247
2015
Q2 		$48K Buy
+820
New +$50.6K 0.03% 177

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Harfst & Associates's TEVA Position: Q3 2017 in Review

Harfst & Associates sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 100 shares — an estimated $3K sold.

Harfst & Associates first reported a position in TEVA in Q2 2015 and held it in 5 quarters. The position peaked at $48K in Q2 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Harfst & Associates reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Harfst & Associates sold 100 Teva Pharmaceuticals shares in Q3 2017, an estimated $3K.
  • Harfst & Associates first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Harfst & Associates's Teva Pharmaceuticals position peaked at $48K in Q2 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Harfst & Associates's 13F filing for Q3 2017, filed 7 Nov 2017.